Ethical issues in psychopharmacology

被引：15
作者：
McHenry, L. [1 ]
机构：
[1] Calif State Univ Northridge, Dept Philosophy, Northridge, CA 91330 USA
来源：
JOURNAL OF MEDICAL ETHICS | 2006年 / 32卷 / 07期
关键词：
D O I：
10.1136/jme.2005.013185
中图分类号：
B82 [伦理学（道德学）];
学科分类号：
摘要：
The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry resents a serious moral problem for the corporate model of medicine. In this paper I examine ethical issues relating to the efficacy and safety of these drugs. Pharmaceutical companies have a moral obligation to disclose all information in their possession bearing on the true risks and benefits of their drugs. Only then can patients make fully informed decisions about their treatment.
引用
收藏
页码：405 / 410
页数：6
相关论文
共 51 条
[1]  
*AM PSYCH ASS, 2000, DIAGN STAT MAN MENT, P192
[2]  
ANGELL M, 2004, TRUTH DRUG CO THEY D, P125
[3]  
ANTONUCCIO DO, PREVENTION TREATMENT
[4]  
ASBERG M, 1986, J CLIN PSYCHIAT, V47, P23
[5]  
ASHCROFT G, 2000, PSYCHOPHARMACOLOGIST, V3, P194
[6]  
ASHCROFT GW, 1966, LANCET, V2, P1049
[7]   5-HYDROXYINDOLES IN HUMAN CEREBROSPINAL FLUIDS [J].
ASHCROFT, GW ;
SHARMAN, DF .
NATURE, 1960, 186 (4730) :1050-1051
[8]  
ASHCROFT GW, 1972, LANCET, V2, P573
[9]   Suicide attempts in clinical trials with paroxetine randomised against placebo [J].
Aursnes, Ivar ;
Tvete, Ingunn Fride ;
Gaasemyr, Jorund ;
Natvig, Bent .
BMC MEDICINE, 2005, 3 (1)
[10]   Uneasy alliance - Clinical investigators and the pharmaceutical industry [J].
Bodenheimer, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1539-1544
123456